Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23

  • Home / Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23

Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23

This symposium took place on 29th September 2017, as part of the 47th Annual European Society for Dermatological Research (ESDR) meeting in Salzburg, Austria

Chairpersons: Antonio Costanzo,1 Carle Paul2
Speakers: Antonio Costanzo,1 Carle Paul,2 Flavio Caprioli3,4

1. Dermatology Unit, Department of Biomedical Sciences, Humanitas
University; Skin Pathology Laboratory, Humanitas IRCC, Milan, Italy
2. Department of Dermatology, Paul Sabatier University and Hôpital Larrey, Toulouse, France
3. Department of Pathophysiology and Transplantation, University of Milan; Unit of Gastroenterology
and Endoscopy, Fondazione IRCCS Cà Granda, Ospedale Policlinico of Milan, Milan, Italy

Disclosure: Prof Costanzo has received research support and/or honoraria from Celgene, Janssen, Leo Pharma, AbbVie, Pfizer, and Novartis; he is also a member of the scientific advisory board for Sanofi, Janssen, AbbVie, Pfizer, Novartis, and Celgene. Prof Paul has received research support and/or honoraria or consultation fees from AbbVie, Almirall, Amgen, Astellas, Celgene, GlaxoSmithKline, Eli Lilly and Company, Janssen Cilag, Leo Pharma, Pierre Fabre, Novartis, Pfizer, and Sanofi/Regeneron. Dr Caprioli has received research support and/or honoraria or consultation fees from Takeda, MSD, AbbVie, Mundipharma, Giuliani, Janssen, Celgene, and Roche; he has also participated in company sponsored speakers’ bureau for Takeda, MSD, Abbvie, Mundipharma, and Janssen.
Acknowledgements: Writing assistance was provided by Blair Hesp, ApotheCom, London, UK.
Support: The publication of this article was funded by Janssen. The views and opinions expressed are those of the authors and not necessarily Janssen.
Citation: EMJ. 2017;2[4]:52-58.

Meeting Summary

Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis. Dr Caprioli discussed the role of the T helper (Th)17 cell lineage and its accompanying cytokines in autoimmune diseases. Prof Paul discussed the latest clinical trial data for therapies targeting the interleukin (IL)-17/IL-23 axis in patients with psoriasis, and how this is changing the treatment landscape. The symposium was followed by a question and answer session.

Click here to view the full symposium.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

The post Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23 appeared first on European Medical Journal.

About Post Author

Medical CPD & News

The Digitalis CPD trawler searches the web for all the latest news and journals.

Privacy Preference Center

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.